MARKET

BCYC

BCYC

Bicycle Therapeutics Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.28
-0.49
-1.90%
Closed 16:01 08/17 EDT
OPEN
25.49
PREV CLOSE
25.77
HIGH
26.06
LOW
24.52
VOLUME
376.56K
TURNOVER
--
52 WEEK HIGH
62.08
52 WEEK LOW
12.08
MARKET CAP
750.21M
P/E (TTM)
-8.3098
1D
5D
1M
3M
1Y
5Y
--HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating
--HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating
MT Newswires · 08/05 09:49
Bicycle Therapeutics: Q2 Earnings Insights
  Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 08/04 14:01
Bicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69M
Bicycle Therapeutics press release (<span class=...
Seekingalpha · 08/04 13:05
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CAMBRIDGE, England & BOSTON, August 04, 2022--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financi...
Business Wire · 08/04 10:59
Bicycle Therapeutics Announces Publication Of Article In Bioconjugate Chemistry, Describing An Extension Of Its Proprietary Technology Platform Based On Bicyclic Peptides
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an
Benzinga · 08/02 22:14
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
CAMBRIDGE, England & BOSTON, August 02, 2022--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that a...
Business Wire · 08/02 20:05
Where Bicycle Therapeutics Stands With Analysts
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Benzinga · 07/28 15:41
--Barclays Initiates Bicycle Therapeutics at Overweight With $30 Price Target
--Barclays Initiates Bicycle Therapeutics at Overweight With $30 Price Target
MT Newswires · 07/28 08:07
More
No Data
Learn about the latest financial forecast of BCYC. Analyze the recent business situations of Bicycle Therapeutics Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
57.14%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BCYC stock price target is 54.86 with a high estimate of 74.00 and a low estimate of 30.00.
High74.00
Average54.86
Low30.00
Current 25.28
EPS
Actual
Estimate
-0.74-0.56-0.37-0.19
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 114
Institutional Holdings: 23.36M
% Owned: 78.78%
Shares Outstanding: 29.68M
TypeInstitutionsShares
Increased
27
2.12M
New
25
1.90M
Decreased
41
2.43M
Sold Out
19
802.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist. The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Webull offers kinds of Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ:BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.